PTC Therapeutics, Inc.

534 articles with PTC Therapeutics, Inc.

• PTC Therapeutics Reports Grants Under Nasdaq Listing Rule 5635(c)(4)

  12/4/2020

   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 2, 2020 it approved non-statutory stock options to purchase an aggregate of 41,955 shares of its common stock and 20,735 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 47 new employe

• PTC Announces Translarna™ Approval in Russia for the Treatment of Duchenne Muscular Dystrophy

  12/4/2020

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been granted marketing approval in the Russian Federation for nonsense mutation Duchenne muscular dystrophy (nmDMD).

• PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia

  11/30/2020

  PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the registration-directed Phase 3 MOVE-FA study evaluating vatiquinone (PTC743) in children and young adults with Friedreich ataxia (FA).

• PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference

  11/19/2020

   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1 st at 11:45 a.m. ET . The presentation will be webcast live on the Events and Presentations page under the investor relations section of

• PTC Therapeutics Announces Key Regulatory Designations for PTC596 to Advance Treatment of Two Rare Oncology Indications

  11/18/2020

  PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted PTC596 both Orphan Drug Designation and Fast Track designation for the potential treatment of leiomyosarcoma (LMS), a rare type of cancer that affects smooth muscle tissue.

• PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program

  11/17/2020

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. PTC518 was identified from PTC's splicing platform and is being developed for the treatment of

• PTC Therapeutics Highlights Data on High Disease Burden and Value of Treatment Across Two Rare Diseases

  11/16/2020

  - AADC deficiency associated with high and accumulating disease burden, demonstrating the need for access to an effective therapy - - Patient and caregiver quality of life study reveals real-life impact of nonsense mutation Duchenne muscular dystrophy and reinforces value of treatment -

• PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

  10/29/2020

  - Evrysdi™ makes rapid progress with multiple international approvals and strong U.S. launch - - Total net revenue of $118.4 million, 66% YoY increase; Total net product revenue of $82.7 million, 16% YoY increase - - Initiated registration-directed trial with vatiquinone (PTC743) for mitochondrial epilepsy - ,

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 28, 2020

  10/28/2020

  PTC Therapeutics, Inc. announced that on October 23, 2020 it approved non-statutory stock options to purchase an aggregate of 18,610 shares of its common stock and 6,860 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 18 new employees.

• PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences

  10/28/2020

   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Credit Suisse 29 th Annual Virtual Healthcare Conference Wednesday, November 11 th at 9:30 a.m. ET Barclays Virtual Gene Editing & Gene Therapy Summit Monday, November 16 th

• PTC Therapeutics and AADC Family Network Announce First-Ever AADC Deficiency Awareness Day in Massachusetts

  10/22/2020

  - Massachusetts signs proclamation declaring Oct.23 as AADC Deficiency Awareness Day - - PTC hosts Facebook Live event featuring leaders from AADC Family Network, MassBio, and Boston Children's Hospital -

• Evrysdi™ (risdiplam) Continues to Make Global Progress for the Treatment of Spinal Muscular Atrophy

  10/21/2020

   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™ (risdiplam) was approved in Brazil by the National Health Surveillance Agency (ANVISA) for the treatment of spinal muscular atrophy (SMA).

• 

  Clinical Catch-Up: September 28-October 2

  10/5/2020

  Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.

• Two-Year Data of Evrysdi™ (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental Milestones

  9/28/2020

  PTC Therapeutics, Inc. announced that two-year data from Part 1 of the FIREFISH study demonstrated that infants on Evrysdi™ continued to improve and achieve motor milestones.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 25, 2020

  9/25/2020

  PTC Therapeutics, Inc. announced that on September 21, 2020 it approved non-statutory stock options to purchase an aggregate of 75,670 shares of its common stock and 12,845 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 22 new employees.

• PTC Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit

  9/24/2020

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 1 st at 9:00 a.m. ET . The presentation will be webcast live on the Events and Presentations page under the investor relations section of P

• PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders

  9/9/2020

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new program that provides genetic testing and counseling for people who may have a neurotransmitter disorder, such as aromatic L-amino acid decarboxylase (AADC) deficiency

• PTC Therapeutics' 2020 STRIVE Awards for Duchenne Muscular Dystrophy Recognize Four Patient Advocacy Organizations

  9/8/2020

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the winners of its sixth annual STRIVE Awards grant program for Duchenne muscular dystrophy.

• PTC Therapeutics to Present at the Cantor Virtual Global Healthcare Conference

  9/3/2020

   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Cantor Virtual Global Healthcare Conference on Thursday, September 17 th at 9:20 a.m. ET . The presentation will be webcast live on the Events and Presentations page under the investor relations section of P

• PTC Therapeutics Announces First Commercial Milestone Payment Following U.S. FDA Approval of Evrysdi™ (risdiplam)

  8/26/2020

   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company achieved a $20 million milestone payment from Roche under its License and Collaboration Agreement. The milestone payment was triggered by the first commercial sale of Evrysdi™ (risdiplam) in the U.S. Evrysdi™ was approved by the Food and Drug Admini